- Catherine A. Loynes
- Jou A . Lee
- Anne L. Robertson
- Michael J. G. Steel
- Felix Ellett
- Yi Feng
- Bruce D. Levy
- Moira K. B. Whyte
- Stephen A. Renshaw
- Download as Adobe PDF
Rights statement: Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).
Final published version, 3.15 MB, PDF document
Licence: Creative Commons: Attribution (CC-BY)
Original language | English |
---|
Article number | eaar8320 |
---|
Number of pages | 14 |
---|
Journal | Science Advances |
---|
Volume | 4 |
---|
Issue number | 9 |
---|
DOIs | |
---|
Publication status | Published - 5 Sep 2018 |
---|
Neutrophils are the first immune cells recruited to a site of injury or infection, where they perform many functions. Having completed their role, neutrophils must be removed from the inflammatory site—either by apoptosis and efferocytosis or by reverse migration away from the wound—for restoration of normal tissue homeostasis. Disruption of these tightly controlled physiological processes of neutrophil removal can lead to a range of inflammatory diseases. We used an in vivo zebrafish model to understand the role of lipid mediator production in neutrophil removal. Following tailfin amputation in the absence of macrophages, neutrophillic inflammation does not resolve, due to loss of macrophage-dependent handling of eicosanoid prostaglandin E2 (PGE2) that drives neutrophil removal via promotion of reverse migration. Knockdown of endogenous PGE synthase gene reveals PGE2 as essential for neutrophil inflammation resolution. Furthermore, PGE2 is able to signal through EP4 receptors during injury, causing an increase in Alox12 production and switching toward anti-inflammatory eicosanoid signaling. Our data confirm regulation of neutrophil migration by PGE2 and LXA4 (lipoxin A4) in an in vivo model of inflammation resolution. This pathway may contain therapeutic targets for driving inflammation resolution in chronic inflammatory disease.
ID: 70467671